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with dobutamine versus dipyridamole stress
R. SCIAGRÀ 1, O. ZOCCARATO 2, G. BISI 3, A. PUPI 1
Aim. Animal studies suggest an interference of dobuta-
mine on [99mTc]sestamibi uptake. In this study dobuta-
mine was compared to dipyridamole rest-stress
[99mTc]sestamibi uptake ratio (UR). 
Methods. Twenty-five patients with suspect coronary
artery disease (CAD) underwent rest, dobutamine, and
dipyridamole [99mTc]sestamibi SPECT at 24-h intervals
and coronary angiography. UR was calculated separately
for each coronary territory considering injected dose
and acquisition delay. 
Results. There were 38 CAD territories in 20 patients. On
a patient basis, dipyridamole SPECT sensitivity was 85%,
versus 70% for dobutamine. On a territory basis, sensi-
tivity was 66% versus 42% (P<0.05), and specificity 92%
versus 86%, respectively for dipyridamole versus dobu-
tamine. In the 38 CAD territories, dipyridamole UR was
-4.1±29.4%, and dobutamine UR was -13.1±19.9%
(P<0.05). In the 37 no-CAD territories, UR was 34±23.6%
for dipyridamole and -0.4±17.8% for dobutamine
(P<0.0001). UR difference between CAD versus no-CAD
territories was larger using dipyridamole (P<0.0001)
than dobutamine (P<0.005). 
Conclusion. The UR comparison confirms that [99mTc]ses-
tamibi uptake underestimates the blood flow hetero-
geneity induced by dobutamine more than that pro-
duced by dipyridamole. 
KEY WORDS: Dipyridamole - Dobutamine - Coronary artery
disease.
In patients unable to perform exercise stress testingand with contraindications to coronary vasodilators,
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dobutamine is the alternative stress modality for myocar-
dial perfusion imaging.1-3 Several clinical studies have
demonstrated that dobutamine perfusion imaging is
reliable for detection and prognostication of coronary
artery disease (CAD) and do not report tracer-related dif-
ferences in diagnostic reliability.2, 4-9 Animal studies,
however, demonstrated that [99mTc]sestamibi underes-
timates the blood flow heterogeneity induced by dobu-
tamine, possibly because of a direct adverse effect of
dobutamine on myocardial [99mTc]sestamibi uptake.10-
13 This could have important implications in patients
with mild coronary stenosis.13 In humans, no data are
so far available that support an interference of dobut-
amine on [99mTc]sestamibi myocardial uptake. The study
purpose was to examine quantitatively the changes in
[99mTc]sestamibi uptake induced by dobutamine in
patients with suspect CAD comparing them with the
changes induced by dipyridamole.
Materials and methods
Patient population and study protocol
The study cohort was consecutively selected among
patients referred to our center for evaluation of chest
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pain of suspect coronary etiology. Patients with already
established diagnosis of CAD, previous myocardial
infarction, other cardiac disease including rhythm dis-
turbances, valvular heart disease, and cardiomyopa-
thy or with contra-indications to dipyridamole or
dobutamine administration were excluded. The final
study group included 25 patients (17 males and 8
females, mean age 60±9 years). 
All patients performed resting baseline, dipyri-
damole and dobutamine [99mTc]sestamibi single-pho-
ton emission computed tomography (SPECT) and
coronary angiography. The three SPECT studies were
performed 24-hour apart, in random order. Coronary
angiography was performed according to the study
protocol within 15 days of scintigraphic imaging. No
patient was receiving cardioactive or xanthine con-
taining drugs. The clinical conditions of all patients
remained stable for the whole study. The local Ethics
Committee on Human Research approved the study
protocol. All patients gave informed consent to par-
ticipate in the study. 
Coronary angiography
Selective coronary angiography was performed in
multiple views using the percutaneous transfemoral
approach. The degree of lumen narrowing was visu-
ally estimated with the aid of calipers. Diameter steno-
sis was considered significant if ≥50%.
Dipyridamole test
Patients avoided beverages containing xanthine for
at least 24 hours before the test. Dipyridamole was
infused under electrocardiographic and blood pres-
sure monitoring in a dose of 0.56 mg/kg over 4 min
followed by a 4 min interval and then by a second
dose of 0.28 mg/kg over 2 min. Thus, the cumula-
tive dose was 0.84 mg/kg over 10 min. Infusion was
interrupted at achievement of peak dose, at onset of
ischemia (indicated by chest pain associated with
horizontal or downsloping ST segment depression
≥0.1 mV at 80 ms after the J point or development
of wall motion abnormalities) or at occurrence of
remarkable side effects. Technetium-99m sestamibi
(740 MBq, 20 mCi) was injected 2 min after the com-
pletion of the second dose or earlier if ischemia or
side effects requiring the premature termination of
the test were registered. Aminophylline (120 mg)
was routinely administered i.v. at least 8 min after
tracer injection.
Dobutamine test
Dobutamine was infused intravenously with a
mechanical pump at incremental doses of 10, 20, 30, and
40 µg/kg per min every 3 min, under electrocardio-
graphic and blood pressure monitoring; the maximal
rate (40 µg/kg per min) was maintained for 5 min. End-
points of the test were achievement of peak dose, devel-
opment of ischemia (as previously defined for the dipyri-
damole test), or the occurrence of severe side effects.
Atropine (0.5-1 mg i.v.) was injected in patients in whom
at 40 µg /kg per min the heart rate was persistently
<85% of the age-predicted maximal value. Technetium-
99m sestamibi (740 MBq, 20 mCi) was injected after 1
min of the predetermined maximal infusion rate, and the
drug infusion was subsequently continued for 5 min. The
tracer injection took place earlier in case of the occur-
rence of one of the criteria requiring the premature ter-
mination of the test. In case of atropine administration,
we injected [99mTc]sestamibi after 3 min. Atenolol (up to
2.5 mg in 5 mL) was available to treat side effects.
Technetium-99m sestamibi SPECT
SPECT was collected 60 min after [99mTc]sestamibi injec-
tion. We used an Elscint Apex SP4 γ-camera equipped
with an ultra-high resolution collimator, with a 20% win-
dow centered at the 140 keV photopeak of technetium-
99m. Sixty projections of 20 seconds each were acquired
in step and shoot mode over a 180° arc, on 64 × 64 matri-
ces using a zooming factor of 1.4. The image recon-
struction was performed with filtered backprojection
using a Wiener resolution recovery filter. No attenuation
or scatter correction was used. The transaxial slices were
realigned along the heart axis obtaining short-axis, ver-
tical, horizontal long-axis slices, and polar maps of the
regional [99mTc]sestamibi distribution were obtained. Each
polar map was normalized for peak myocardial activity
and compared with the normal limits obtained in 50 sex-
matched subjects with <5% probability of coronary artery
disease; pixels with tracer uptake falling more than 2.5 SD
below mean normal values were considered abnormal.14
To make diagnosis of CAD, a coronary artery territory
should include at least 10% of abnormal pixels (12% for
the right coronary artery territory).15
Uptake ratio calculation
For the calculation of the uptake ratio (UR),16-18 the
counts within the resting polar map were corrected by
the injected activity and the delay between injection
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where RAacq.time is the activity at the moment of rest-
ing SPECT acquisition and RAinj.time the injected activ-
ity measured in the syringe before administration with
a dose calibrator. Similarly, the stress polar maps were
corrected according to the formula:
where SA = activity at the moment of stress images
acquisition (either dipyridamole or dobutamine). The
stress counts were further corrected with factors relat-
ed to normalization and backprojection algorithm
according to the formula:
where Krest/stress includes all normalization factors
used during the procedure of filtered backprojection
reconstruction. Finally, UR was derived from the for-
mula:
where Ir and Is are the polar map images of stress
and rest, respectively.
UR was shown on a colour coded polar map display
on which the three coronary artery territories were
identified as usual (Figure 1).14, 15 For each coronary
artery territory the average UR was calculated and
expressed as percent of the baseline uptake.
Statistical analysis
Continuous variables were expressed as mean value
± standard deviation and were compared with the
Student’s t test for paired or independent samples as
appropriate, or with the Pearson correlation coefficient;
the comparison of proportions was made using the Fisher
exact test. A P value <0.05 was considered significant. 
Results
General findings
According to coronary angiography, 20 patients
were affected by significant CAD (8 1-vessel, 6 2-ves-
sels, and 6 3-vessels CAD) while five had normal
coronary arteries. Therefore, a total of 38 coronary
artery territories were affected by significant CAD. In
resting SPECT, no patient showed abnormal tracer
uptake. 
Dipyridamole test
All patients completed without adverse effects the
high-dose infusion protocol. The mean rate-pressure
product at the moment of tracer injection was
11465±1514 beats/min × mmHg, significantly higher
than the corresponding baseline value (9 111±777
beats/min × mmHg, P<0.0001). Anterior chest pain
of possible ischemic origin was reported by eight
patients and in six of these eight patients and in fur-
ther two subjects, electrocardiographic modifications
suggestive of ischemia were registered. In the dipyri-
damole images, 28 territories fulfilled the criteria for
significant CAD; 25 of these territories showed a sig-
nificant stenosis in coronary angiography. Therefore,
the sensitivity of dipyridamole [99mTc]sestamibi SPECT
was 66% for identification of individual affected ter-
ritories, with 92% specificity. On a patient basis, 17 out
of 20 patients were correctly recognized as affected by
CAD in at least 1 coronary artery territory (sensitivity
85%). 
Dobutamine test
The dobutamine infusion protocol was completed
in 18 patients. Of them, four reported anginal pain,
one had ischemic electrocardiographic changes and
one both angina and ischemic electrocardiographic
changes. In seven patients dobutamine infusion was
precociously interrupted because of anginal pain (four
cases), of ischemic electrocardiographic changes (one
case), or of both (two cases). The mean rate-pres-
sure product at the moment of tracer injection was
19993±3370 beats/min × mmHg, significantly higher
than the related baseline value (8 950±865 beats/min
× mmHg, P<0.0001) and than the dipyridamole value
(P<0.0001). In dobutamine SPECT, 22 territories
showed an abnormal uptake, with 42% sensitivity
(P<0.05 vs. dipyridamole) and 86% specificity for iden-
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basis, 14 out of 20 CAD patients had an abnormal
uptake in at least one territory with significant obstruc-
tion (sensitivity 70%). Among CAD patients there were
two subjects with typical angina and one with typical
angina and ischemic electrocardiograohic changes
during dobutamine test that had normal tracer uptake
in SPECT images. With one single exception, all false
negative CAD patients had completed the dobuta-
mine test reaching the target heart ratio. 
Uptake ratio
In the 38 territories with significant coronary steno-
sis, the dipyridamole UR was -4.1±29.4% and the
dobutamine UR was -13.1±19.9% (P<0.05). The relat-
ed values in the 37 coronary territories without
obstruction were 34±23.6% for dipyridamole and
-0.4±17.8% for dobutamine (P<0.0001). Therefore, a
highly significant UR difference was registered
between stenotic and normal territories using dipyri-
damole (P<0.0001). The UR difference between stenot-
ic and normal territories was slightly less significant
using dobutamine (P<0.005) (Figure 2).
There was a significant inverse correlation between
Figure 1.—Example of UR calculation: top left: stress polar map, top right baseline resting polar map; bottom left UR polar map. A)
Dipyridamole SPECT showing uptake defects in all coronary artery territories; B) dobutamine SPECT showing an inferior defect only. The
more positive UR and the greater contrast in dipyridamole versus dobutamine UR polar map are apparent. In the color scale red=highest acti-























Figure 2.—Histogram showing the UR under dipyridamole (white
bars) and under dobutamine (black bars) in the territories with ver-
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extent of abnormal uptake and UR both using dipyri-
damole (r=-0.58, P<0.0001), and using dobutamine
(r=-0.46, P<0.0001). There was a significant inverse cor-
relation as well between degree of coronary artery
obstruction and dipyridamole UR (r=-0.64, P<0.00001),
and this correlation was significantly closer (P<0.05)
than the corresponding correlation with dobutamine
UR (r=-0.38, P<0.001) (Figure 3). 
Discussion
Coronary vasodilators, such as dipyridamole or
adenosine, induce maximal increase in coronary blood
flow, with measured values 4- to 5-fold the baseline
level.19 In stenotic territories, flow may increase to a
more limited extent, or be actually decreased because
of coronary steal mechanisms.20 Inotropic stimulators
like dobutamine produce at high dosage an increase
in oxygen demand, mainly because of increase in
heart rate and myocardial contractility. Consequently,
they induce coronary dilatation to meet the increased
demand, with a rise in coronary blood flow in normal
territories that has been reported to range from 3- to
5-times the baseline value.21, 22 In territories subtend-
ed with stenotic vessels true ischemia is to be expect-
ed, and can be identified both by perfusion and by
functional imaging, mainly echocardiography.23
Various animal studies, however, suggest a possible
interference of dobutamine on [99mTc]sestamibi uptake,
and this would imply that other tracers should be
preferable to [99mTc]sestamibi in case of dobutamine
stress.10-13 The hypothesized mechanism is a dobuta-
mine-induced calcium influx into the mitochondria,
with consequent reduction of the mitochondrial neg-
ative transmembrane potential.24, 25 Although there
are enough clinical reports about dobutamine
[99mTc]sestamibi imaging to indicate that this potential
interference has limited importance in clinical prac-
tice,2, 6-8 the issue has been never completely clari-
fied. A main reason for this is the difficulty to quan-
tify in humans the [99mTc]sestamibi uptake under dobu-
tamine. To overcome this problem, we examined a rel-
ative parameter, the stress-rest UR, and we compared
it in the same patients using both dipyridamole and
dobutamine. Although UR is just a coarse parameter
that does not define the absolute value of tracer uptake
in the myocardium, we thought that by assessing it in
normal and stenotic territories of the same subjects,
and having as reference the values obtained using
dipyridamole, our data could be of some interest. 
We could demonstrate that in coronary territories
without epicardial vessel obstruction, the increase in
[99mTc]sestamibi uptake induced by dobutamine was
significantly lower than that induced by dipyridamole.
Because positron emission tomography studies indi-
cate that there are no differences in the maximal flow
that can be achieved using dipyridamole or dobuta-
mine our data would confirm some interference of
dobutamine on [99mTc]sestamibi uptake. In the pres-
ence of coronary stenosis, there was on average a
slight decrease in [99mTc]sestamibi uptake with both
dobutamine and dipyridamole. Because most of our
patients had severe coronary stenoses this finding is
not completely surprising, since in these cases even
dipyridamole may induce true ischemia. It would
have been reasonable to expect more pronounced
decreases using a stressor with ischemic properties
such as dobutamine, but this was not the case.
Consequently, we observed that the difference in
stress-induced uptake changes between normal and
stenotic coronary artery territories was clearly greater
using dipyridamole than dobutamine. 
When these data were compared with the capabil-
ity of the two stressors to identify significant CAD
using a standardized quantitative approach to SPECT
evaluation, dobutamine SPECT was found to quite












Figure 3.—Correlation between severity of CAD (percent lumen
obstruction) and UR under dipyridamole (white bars, dashed line) and
under dobutamine (black bars, solid line). Bars show the mean UR for
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is in agreement with the several reports that examined
the reliability of [99mTc]sestamibi dobutamine SPECT.2,
6-8 However, it appeared that on a coronary artery
basis dipyridamole was superior to dobutamine in
terms of sensitivity, without major differences in speci-
ficity. 
The small and selected patient population is a first
limitation of our study. However, this study was not
aimed to compare the diagnostic power of the two
stressors, but to the comparison of their URs, and to
the best of our knowledge this comparison had nev-
er been performed before. We did not use gated
SPECT in this study, and therefore we cannot define
how far the evaluation of left ventricular function
could influence the diagnostic performance of the
two stressors and possibly help to overcome some
limits of dobutamine.26 On the other hand, most of the
literature about [99mTc]sestamibi dobutamine SPECT
is based on nongated data.2, 6-9 UR remains a very
coarse method to measure the true tracer uptake by
the myocardium. By evaluating the UR under dipyri-
damole in the same patients we tried to partly over-
come this limitation. Given the heterogeneity of the
reported myocardial blood flow values under dobu-
tamine,21, 22 the lack of flow measurements in our
patients precludes the possibility to definitely demon-
strate that the lower UR was not related to a lower flow
increase. Finally, our study does not give any data
about the mechanisms that cause the interference of
dobutamine on [99mTc]sestamibi uptake. 
Conclusions
In conclusion, our data suggest that using dobuta-
mine the disparity in [99mTc]sestamibi uptake between
normal and stenotic coronary artery territories is rel-
atively less marked than using dipyridamole and that
this difference could imply a less accurate detection
of individual CAD territories with possible underesti-
mation of CAD extent. This study supports to restrict
the use of dobutamine stress for [99mTc]sestamibi
myocardial perfusion SPECT to the few cases in which
it is indicated by the current recommendations.3
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